Morgan Stanley Raises Price Target for Eli Lilly and Company Based on Updated Biopharma Models
Morgan Stanley increased its price target for Eli Lilly and Company (LLY) to $1,327 from $1,313, maintaining an Overweight rating. The update is based on revised financial models incorporating IQVIA data and intra-quarter performance ahead of first-quarter earnings. Eli Lilly also reported positive results from a Phase 3 trial of Jaypirca in CLL/SLL patients.
Tickers: $LLY
Topics: Biopharma Model Clinical Trial Results CLL/SLL Eli Lilly and Company Jaypirca Morgan Stanley Price Target